Crowdfunding Project Looks for a “Better Rapamycin”

News
#61

That’s probably the most important part as it’s what driving the sales. People are betting on owning a share of a FDA approved drug for aging?

1 Like
#62

Yes something like this. Not all of the drugs on Pump are FDA approved. The great thing about the Rapamycin + Doxycycline combo is both are FDA approved so it could be fast tracked compared to Omipalisib + Doxycycline.

1 Like
#63

Have you personally tried the combo regimen?

#64

Personally as in taken it myself? No. I take rapamycin 6mg once a week. I’m open to adding in doxycycline low dose alongside this. It’s something I’ve been considering, and given the incredible lifespan data we have seen from this on previous tests it just adds credence to the combination.

3 Likes
#65

I think you misunderstood my question. I meant FDA approved for aging. How is the drug or combination expected to be monetized after human trials?

#66

As a general observation, people can parent unique combinations of generic drugs for new indications, and then sell it as a new drug.

4 Likes
#67

The long term value of any of the trading is always in expectation of that. It’s the return. I don’t see why that shouldn’t be primary in any marketing.

#68

Longevity Technology article on Rapamycin Longevity Lab:

3 Likes
#69

The 301 mTOR modulator compounds tested in the first half of the mTOR modulator lifespan study have been added to the Rapamycin Longevity Lab Longevity Intervention Database (LID): Rapamycin Longevity Lab - It's time to speed things up!
To see them, enter “RLL” into the ‘Tags’ field.

Read this X post for more information from Krister:
https://x.com/KristerKauppi/status/1972964640482279706

3 Likes
#70

Thanks for sharing, @AustraliaLongevity! And big thanks for all the great support in the project. Now the next goal is to get the last remaining 300 compounds screened as well in phase 2 of the project. Please reach out if you want to support or if you know someone who may be interested in doing so. Just to give a thumbs up or share the social media post is also a great way to support the project if you are not able to financially help out :pray:

Here is also the LinkedIn post:

2 Likes
#71

A suggested combo regimen of rapamycin and doxy by perplexity:

*** Rapamycin:**

  • Role: Inhibits mTOR, inducing autophagy and metabolic stress.
  • Suggested Use: 1–2 mg daily or 5–10 mg weekly (common in research for mTOR inhibition). Low, intermittent doses may reduce side effects while maintaining efficacy.
  • Timing: Once weekly (e.g., Monday) to sustain mTOR suppression, as effects were reversible after short-term treatment in the study.
    *** Doxycycline:**
  • Role: Disrupts mitochondrial function, enhances mitophagy, amplifies metabolic stress.
  • Suggested Use: 100 mg daily (standard antimicrobial dose, often used in cancer studies for mitochondrial targeting). Continuous low-dose may align with study’s long-term treatment efficacy.
  • Timing: Daily, morning or evening, to maintain mitochondrial disruption and synergize with rapamycin’s autophagy induction.
    *** Weekly Stack Example:**
  • Monday: Rapamycin (5–10 mg, single dose) + Doxycycline (100 mg daily, continue through week).
  • Tuesday–Sunday: Doxycycline (100 mg daily).
  • Rationale: Rapamycin’s weekly pulse sustains mTOR inhibition; daily Doxy maintains mitochondrial stress and mitophagy, as seen in ~2/3 cell line efficacy.
3 Likes
#72

Yes, we are exploring this combo at the Rapamycin Longevity Lab. Here is the current monthly update of the pipeline.

X post
https://x.com/KristerKauppi/status/1975501359974629770

LinkedIn post

4 Likes
#73

I don’t myself like the effect doxy has on mitochondria

:jigsaw: Summary

Category Effect
Target Mitochondrial 30S ribosome
Primary effect Blocks mitochondrial protein synthesis
Secondary effects ↓ ETC complexes I–V, ↓ ATP, ↑ glycolysis
Stress response Activates UPRmt and mitonuclear signaling
Morphology Fragmentation, loss of cristae
Reversibility Yes, after withdrawal
Research caution Confounds metabolic/aging experiments
2 Likes
#74

Lets see if different doses protocols result in the same effect. My guess is that this is not the case. Like with many things in life. Too much water can cause really bad effects and even result in death but the right amount of water has great effects.

3 Likes
#75

It may be that a low dose has useful hormetic effects, but it does not strike me as a priority as an intervention.

1 Like
#76

Do you have any suggestion on a combo that may perform better than Omipalisib + Doxycycline in multiple species? Rapamycin Longevity Lab’s goal is to explore and accelarate research around mTOR inhibitor based combinational therapies so we start to push the boundaries of human longevity. So just reach out if there are some things that should be looked at. We are going to do some big things this year so exciting things are coming! :slight_smile:

1 Like
#77

I am currently wondering about proline

#78

As interesting as mechanistic theories are, lifespan data is a much better metric to go by. Impressive lifespan data can unlock new mechanistic insights.

2 Likes
#79

:eyes: Myo-inositol trispirophosphate (ITPP)

1 Like
#80

Can you create a simple lifespan and healthspan data matrix on that compound on multiple species?

1 Like